REVANCE ALERT: Bragar Eagel & Squire, P.C. is Investigating Revance Therapeutics, Inc. on Behalf of Revance Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Revance Therapeutics, Inc. (Revance or the Company) (NASDAQ: RVNC) on behalf of Revance stockholders.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Saturday, October 16, 2021
Information
Tags: 
Legal, Professional Services, FDA, Jeanne Eagels, Review, Licensure, News, NASDAQ, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GMP, Food, P.C, Telephone
Geotags: 
California, NEW YORK, United States
⚠generated by AI ↴
Summary
Key Points: 
  • Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Revance Therapeutics, Inc. (Revance or the Company) (NASDAQ: RVNC) on behalf of Revance stockholders.
  • Our investigation concerns whether Revance has violated the federal securities laws and/or engaged in other unlawful business practices.
  • Click here to participate in the action.
  • On October 12, 2021, the U.S. Food and Drug Administration (FDA) posted Form 483 to its website citing issues found during the inspection of a Revance facility in July 2021.


Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC) on behalf of Revance stockholders. Our investigation concerns whether Revance has violated the federal securities laws and/or engaged in other unlawful business practices.

Click here to participate in the action.

On October 12, 2021, the U.S. Food and Drug Administration (FDA) posted Form 483 to its website citing issues found during the inspection of a Revance facility in July 2021. The FDA noted a working cell bank as a cause of rejected GMP lots of a product, discrepancies between the manufacturing process compared to that proposed for licensure, and said the Company’s quality unit "lacks the responsibility and authority for the control, review, and approval of outsourced activities…"

On this news, Revance share prices dropped $6.85, or over 25%, to close at $20.45 on October 12, 2021.

If you purchased or otherwise acquired Revance shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Alexandra Raymond by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

Copyright: 
Copyright Business Wire 2021